点击蓝字关注我们编者按由中国医疗保健国际交流促进会血液学分会主办，北京大学人民医院血液病研究所承办的2025北京国际造血干细胞移植学术会议于2025年4月25-26日在北京正式举办。本次会议将“移植的艺术（ART OF TRANSPLANT）”为主题，汇集全球领先的血液学专家，探索造血干细胞移植的技术创新和未来趋势，着力破解基础研究向临床应用转化的关键技术瓶颈，为血液系统疾病治疗开辟新维度。《肿瘤瞭望-血液时讯》现场特邀北京大学人民医院血液科、北京大学血液病研究所张晓辉教授，围绕我国造血干细胞移植事业的技术创新体系构建与全球学术影响力提升等话题进行分享。张晓辉教授：造血干细胞移植作为治疗血液系统恶性肿瘤及严重非恶性疾病的有效手段，其技术体系在国际范围内经历了迅猛发展与规模扩张。基于我国“北京方案”的创新突破及国家政策的多维度支持，当前造血干细胞移植数量呈现显著增长态势，国内各大医疗中心正加速推进移植病房扩建、专业人员培训及技术标准化建设，标志着我国造血干细胞移植事业已步入高速发展的新阶段。“北京方案”作为国际领先的造血干细胞移植体系，在技术创新与临床应用层面持续引领学科发展。最新临床数

点击蓝字 关注我们针对子宫内膜肿瘤发生的关键通路PI3K/AKT/mTOR和MAPK/ERK，许多双药或三药疗联合疗法正在研究中，以改善子宫内膜癌患者的预后，但其疗效有限。PI3K/AKT和RAS/RAF/MEK/ERK通路都涉及mTOR这一重要的下游调控因子，因此mTOR抑制剂是这类患者治疗方案的合理组成部分。此外，二甲双胍（metformin）可诱导代谢变化并激活AMPK，进而抑制mTOR通路，这为Pamela T. Soliman等研究人员探索二甲双胍与mTOR抑制剂替西罗莫司（temsirolimus）联合治疗提供了基础。Pamela T. Soliman, MD, MPH基于mTOR抑制剂联合抗糖尿病药物的疗效Dr. Soliman指出，由于子宫内膜癌患者通常存在胰岛素抵抗，因此解决这一问题并增加外周循环中胰岛素的吸收可能有助于抑制癌症。许多mTOR抑制剂的不良事件之一就是高血糖，添加二甲双胍似乎有一定的作用，但目前还没有完全确定哪些患者从mTOR抑制剂+二甲双胍治疗中获益最多。◎在一项I期临床试验（NCT01529593）中，替西罗莫司联合二甲双胍治疗子宫内膜癌患者的客观缓

London: A class of drugs known as Janus kinase, or JAK, inhibitors, which work by slowing down the immune system, should be the first-line therapy for patients hospitalized for COVID-19, researchers reported in The Lancet Respiratory Medicine. The researchers analyzed individual outcomes of nearly 13,000 adults hospitalized for COVID who participated in 16 randomized trials comparing JAK inhibitors to other drugs or placebos between May 2020 and March 2022. Overall, 11.7 per cent of patients who

以创新为引，共探肥胖管理新范式，助力健康中国建设新征程！2025年进入体重管理年第二年，随着胰高糖素样肽-1受体激动剂（GLP-1RA）等创新减重药物的陆续获批，临床治疗也迎来了更多选择。在此行业革新的关键节点，首届诺和诺德肥胖症论坛（NNOU）于2025年5月18日在杭州顺利召开，本次论坛汇聚行业顶尖专家，共同探讨肥胖防治的新趋势与新方向。论坛聚焦创新药物临床应用、多学科诊疗模式构建等核心议题，旨在推动肥胖症诊疗的标准化与精准化，助力“健康中国 2030”规划中肥胖防控目标的实现。共启新程，共筑未来论坛启幕之际，浙江之江生命健康研究院院长叶真教授与诺和诺德全球高级副总裁兼大中国区总裁周霞萍女士发表致辞，共同擘画肥胖症诊疗未来蓝图，强调以科学共识与创新实践筑牢国民健康根基。叶真教授呼吁在国家政策指引下，构建政产学研紧密合作机制，推动肥胖防控领域的科技创新与服务模式转型，实现健康理念从“治病”到 “健康”的转变。周霞萍女士则从企业视角出发，表明诺和诺德作为行业领军者，不仅致力于提供创新治疗方案，更积极搭建学术交流平台、凝聚多方力量，打造肥胖症防治生态圈，助力“健康中国 2030”目标落地

Data show continuous clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group Women treated with IMNN-001 and standard of care chemotherapy plus PARP inhibitors achieved nearly 12-month increase in PFS compared to standard of care; median OS in IMNN-001 treatment arm not yet reached after more than five years Phase 2 OVATION 2 Study results also published in peer-reviewed journal Gynecologic Oncolo

– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN – – Decision from European Commission expected in the third quarter of 2025 – STAMFORD, Conn., May 23, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the European Medicines Agency’s (EMA) Committe

NEWTON, Mass., May 23, 2025 /PRNewswire/ -- GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, today announced that Dr. Kristopher Wentzel from the Angeles Clinic and Research Institute will present updated clinical and translational data of GV20-0251 monotherapy at the American Society of Clinical Oncology 2025 Annual Meeting, taking place in Chicago, IL on May 30- June 3, 2025. This presentation at ASCO builds on previously presented clinical data of the novel immun

TORONTO and DALLAS, May 23, 2025 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that it has entered into a Development Support Agreement ("DSA") with Salt Lake City-based Intermountain Health, the largest nonprofit health system in the Intermountain West. This agreement creates the framework for the two organizations to partner on a number of future studies evaluat

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the company will present the clinical results from its completed Phase 1 trial of ABX-002 at the 2025 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 27-30, 2025, in Scottsdale, AZ. ABX-002 is a highly potent, oral, thyroid hormone beta receptor (TRβ) selective a

PHILADELPHIA, May 23, 2025 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company pioneering the KIR-CAR platform, today provided additional details on the Trials in Progress poster presentation at the upcoming 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, being held from May 30 – June 3, 2025 in Chicago, IL. The trial Principal Investigator, Janos L. Tanyi, MD, PhD, of the Perelman School of Medicine at the University of Pennsylvania, will present an overview